Time：2026-03-19
(Shanghai, 18 March 2026) Medtide Inc. (03880.HK) announced that it has successfully stood out and been officially awarded the "Leading Enterprise" at the 2026 Forbes China Pioneers in Industry Development selection, co-initiated by Forbes China and Frost & Sullivan, a world-renowned growth consulting firm. This honor is a testament to Medtide Inc.’s profound industrial accumulation in the peptide field, global integrated service capabilities and innovative leadership, marking the high recognition of its professional strength and industrial value in the peptide CRDMO sector by authoritative institutions and the jury.
Against the backdrop of the in-depth integration of the scientific and technological revolution and industrial transformation, this selection takes promoting the high-quality development of the industry as its core proposition, focusing on key sectors such as AI, healthcare, new energy and manufacturing.Through multiple rounds of professional screening and comprehensive evaluation, it systematically identifies pioneering players in each track with outstanding innovation capabilities, development resilience and ecological construction capacity. Aiming to convey the value orientation of long-termism and encourage enterprises to stay focused amid changes and reshape their development paths in the face of challenges, Medtide Inc.’s emergence as a winner among numerous participating enterprises is the industry’s full recognition of its achievements in deepening layout in the track and making continuous innovative breakthroughs, as well as an authoritative certification of its contributions and leading value to the industry.
Dr. Shawn Lee, Co-founder and Executive Director of Medtide Inc.